Editor's Pick: Identifying the Best Ki-67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification
Over the last few years, advances in molecular biology and genome sequencing have made it possible to identify the genetic alterations that underlie different health conditions, and these advances are particularly important in the field of oncology. Thanks to these advanced techniques, there has been a change in the way a disease as complex and heterogeneous as breast cancer (BC) is understood.
